Navigation Links
Echo Therapeutics to Present at the OneMedForum 2011 Conference
Date:1/7/2011

FRANKLIN, Mass., Jan. 7, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at the OneMedForum 2011 annual healthcare conference held January 10-13th in San Francisco, CA.

Dr. Mooney will make a corporate presentation to prospective corporate partners and investors on Tuesday, January 11 at 4:15 PM PST. The Company's presentation will be delivered in the Renaissance Room at The Sir Francis Drake Hotel, Union Square, San Francisco, CA.

About OneMedForum 2011The fourth annual OneMedForum event continues to be a vital connecting point for healthcare/life science-focused emerging companies, business development executives and investors. The three-day event will include industry-focused panel sessions, numerous networking opportunities, and more than 125 presentations by some of the most promising emerging medical device, biotech and health information companies.  OneMedForum San Francisco 2011, runs concurrently with the J.P Morgan conference that provides efficient access to the companies that shape the future of the rapidly changing healthcare landscape.

About Echo TherapeuticsEcho is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.  

Cautionary Statement Regarding Forward Looking StatementsThe statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including the efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2009, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.For More Information:Patrick T. Mooney, M.D.

Media: Richard SternChairman and Chief Executive Officer

Stern & Co.(508) 530-0329

(212) 888-0044
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)...   Click here for supplemental information regarding ... the nation,s largest independent specialty pharmacy, announced today ... acquire Valley Campus Pharmacy, Inc., doing business as ... pharmacy that provides individualized patient care, based in ... 2015, TNH generated approximately $400 million in revenue. ...
(Date:4/28/2016)... BURLINGAME, Calif. , April 28, 2016 /PRNewswire/ ... first-ever widely accessible breast and ovarian cancer risk ... cancer panel analyzing 30 genes that highly impact ... and women. Available today, the Color Test analyzes ... pancreatic, prostate, stomach, and uterine cancers. The Color ...
(Date:4/28/2016)... NEW YORK , April 28, 2016 ... of online consumer insights on healthcare, announced today that ... in their report Cool Vendor in Life Sciences, ... , April 15, 2016.  The report focuses on life-science- ... to gain insight from patients and doctors, confirm medication ...
Breaking Medicine Technology:
(Date:5/3/2016)... , ... May 03, 2016 , ... Elizabeth Murray has ... parrots to join her with one on her shoulder and one on her arm. ... parking lot because of years of mitral valve prolapse. , The valves of the ...
(Date:5/3/2016)... ... ... Excessive panting in the car or cowering when new guests arrive are ... only manifests itself as trembling or ‘tail between the legs,’ but a pet ... about it,” says Dr. Jim Lowe, technical services veterinarian for Tomlyn pet health products ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... been selected by Tidelands Health, a three hospital system in South Carolina, to ... on the lookout for technology that enhances communication, drives workflow efficiencies and improves ...
(Date:5/3/2016)... ... 2016 , ... Boston Children’s Hospital today announced its new pediatric Simulation (SIM) ... or rare procedures in an environment that looks and feels real. , Located in ... inventors and “hackers” to develop and test new devices or software platforms and see ...
(Date:5/3/2016)... OH (PRWEB) , ... May 03, 2016 , ... Each ... a leading cause of death across the United States and account for one death ... and mental impairments or are permanently disabled. HCR ManorCare is launching a video series ...
Breaking Medicine News(10 mins):